RecruitingNCT06788652
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Enrollment
300 participants
Start Date
Feb 4, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- • Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA
Exclusion Criteria2
- Participants known to be participating in investigational studies at the time of liso-cel infusion.
- Participants treated with non-conforming CAR T-cell product.
Interventions
BIOLOGICALLisocabtagene maraleucel
According to US Prescribing Information
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06788652
Related Trials
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT0513102262 locations
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
NCT041865201 location
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT071219465 locations
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
NCT060430111 location
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT070775123 locations